Page
What Is Bendamustine and To Whom Is It Given?
TREANDA® or BENDEKA® (bendamustine) is a type of FDA-approved chemotherapy to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) in the U.S. It has been approved in Europe as a first-line treatment for multiple…
Videos
Evaluating Risk and Progression in High-Risk Smoldering Myeloma
Myeloma expert Dr. Brian G.M. Durie addresses key questions and concerns surrounding this critical stage of myeloma; high-risk smoldering.
Learn about the 20/2/20 criteria, which helps predict the risk of…
News Article
#kNOwMyeloma Reaches Nearly 20 MILLION People in 64 Countries!
The IMF’s 2023 Blood Cancer Awareness Month
By Peter Anton, IMF Vice President, Marketing
For the 2023 Blood Cancer Awareness Month (BCAM), the International Myeloma Foundation (IMF…
Videos
How Close Is the IMF to Curing and Preventing Myeloma?
Myeloma expert Dr. Brian G.M. Durie answers the question: Are we getting closer to a myeloma cure or finding ways to prevent this disease?
Dr. Durie discusses the latest advancements in myeloma treatment and…
News Article
IMF Supports the Bipartisan Cancer Drug Parity Act for Improved Access to Cancer Treatments
The International Myeloma Foundation (IMF) strongly endorses the Cancer Drug Parity Act, co-led by Representatives Glenn Grothman, Suzanne Bonamici, Gus Bilirakis, Joe Morelle, Brian Fitzpatrick, Brian…
News Article
Washington, D.C. November 8, 2023 – In a significant stride toward ensuring equitable access to cancer treatments, Members of the House of Representatives reintroduced the Cancer Drug Parity Act today. The bill has garnered widespread endorsement from prominent healthcare…
News Article
The Role of the Care Partner in Myeloma
Care partners walk alongside their loved ones to help them live well with myeloma
By Robin Tuohy, IMF Vice President, Support Groups
Who is a care partner?
Care partners, also known as “caregivers,” are individuals who provide…
Videos
M-Power Detroit Community Event On Health Empowerment
Focusing on awareness of multiple myeloma in the African American community and living a healthier life.
The M-Power Project realizes the IMF Diversity Initiative's vision, enhancing outcomes for African-American myeloma patients…
Videos
Download Slides
Videos
What Are Some Of the Breakthroughs in Myeloma Research Made By the BSRI?
Myeloma expert Dr. Brian G.M. Durie discusses the groundbreaking advancements in myeloma research through the International Myeloma Foundation's Black Swan Research Initiative (BSRI).
He highlights…
News Article
STUDIO CITY, CA, November 3, 2023 – The International Myeloma Foundation (IMF) is pleased to announce that the organization has been selected as the winner of the 2023 Sanofi HealthEquity Accelerator Award for its Shared Decision-Making among African American and Hispanic…
Page
What Is Elrexfio?
ELREXFIO® (also known as elranatamab-bcmm, the generic drug name) is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. In August 2023, the U.S. FDA granted accelerated approval of Elrexfio for the treatment of adult patients with…
Videos
Disparities Made Simple
Myeloma Made Simple: What Health Disparities Do Minority Patients Face?
Disparities in Myeloma Made Simple! Join Dr. Joseph Mikhael in the latest episode of "Myeloma Made Simple" as he explores the inequities in healthcare faced by socially disadvantaged…
Videos
The International Myeloma Foundation's Asian Myeloma Network
Enhancing multiple myeloma care in Asia and globally.
In this week's #AskDrDurie Myeloma Expert Dr. Brian G.M. Durie breaks down the IMF Asian Myeloma Network (AMN) Summit, where experts discuss groundbreaking…
Page
What Is Talvey?
TALVEY® (also known as talquetamab, the generic drug name) is a bispecific monoclonal antibody with a novel target, GPRC5D, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a…
Videos
The Power of Emotional Freedom Technique
Clinical Psychologist Rebecca Rooney, explores the power of Emotional Freedom Technique (EFT), also known as tapping.
Whether you're a myeloma patient, care partner or just seeking emotional healing, this video provides practical insights into using…
Videos
Replay a fascinating discussion with Dr. Joseph Mikhael, the Chief Medical Officer of the International Myeloma Foundation, as he delves into the latest advancements in multiple myeloma research. Discover how cutting-edge techniques like mass spectrometry are revolutionizing diagnosis and treatment…
Videos
Join us for a replay of a Facebook Live event featuring Beth Faiman, a nurse practitioner from the International Myeloma Foundation Nurse Leadership Board. In this informative session, Beth answers questions and provides insights about multiple myeloma, bone marrow transplants, and various aspects…
Videos
During Blood Cancer Awareness Month, Danielle Doheny, Director of Public Policy and Advocacy at the International Myeloma Foundation (IMF), hosted a live Q&A to discusses myeloma advocacy, health policy, and the importance of patient voices. Discover the impact of "oral parity" and learn how…
Audio
On this episode of “Transforming Biopharma,” Managing Partner of ZS Associates Maria Whitman talks with International Myeloma Foundation (IMF) President and CEO Yelak Biru on how he merged his 25 years of data analytic expertise at Fortune 500 companies with his 28 years of living with the…
News Article
International Myeloma Foundation (IMF) to hold first-ever AMN Awards Ceremony at the 7th AMN Summit in Bangkok, Thailand on October 21
BANGKOK, OCTOBER 21, 2023—The International Myeloma Foundation (IMF) announced that it will be holding its first-ever Asian Myeloma…
News Article
The European Medicines Agency's (EMA) Committee for Human Medicines (CHMP) has recommended conditional marketing authorization for ELREXFIOTM (elranatamab) as a standalone treatment for adult patients with relapsed and refractory multiple myeloma. These patients must have undergone at least three…
Videos
As overall survival in myeloma continues to increase, there is an opportunity to improve outcomes further with nutrition and lifestyle interventions and this can no longer be ignored. In this IMF Living Well With Myeloma Webinar, Dr. Shah discusses the scientific evidence behind dietary guidance…
Videos
SpineJack and How It Can Benefit Myeloma Patients
SpineJack involves inserting a small jack into a collapsed vertebra, lifting the collapsed area to create space for the injection of hardening cement. This process aims to raise the vertebra's height and alleviate pain. SpineJack could be…
Videos
The International Myeloma Working Group's Primary Focus is Identifying Unmet Needs within the Myeloma Community and Advancing Myeloma Knowledge
The IMWG has developed crucial criteria for diagnosis (such as the "2/20/20 system" for high-risk smoldering myeloma), the Immune Therapy Registry, the…
News Article
In this interview with Cure Today, IMF Chief Medical Officer Dr. Joseph Mikhael discusses recent advancements in stem cell mobilization in autologous stem cell transplants. These advancements involve using G-CSF and Aphexda in combination to improve stem cell collection efficiency compared to G-CSF…
News Article
AbbVie has announced data from its Phase III CANOVA study, which evaluated the safety and efficacy of venetoclax plus dexamethasone for patients with t(11;14)-positive relapsed or refractory multiple myeloma. The results did not show a significant improvement in progression-free survival…
Videos
Description:
High-level overview of autologous stem cell transplant (ASCT) for treatment of multiple myeloma.
Module Objectives:
- Review concepts of who should undergo an ASCT, eligibility and treatment decision making
- Provide a brief overview of the…
Myeloma Made Simple: Treatment for Patients Not Undergoing Transplant (Non-ASCT Transplant Eligible)
Videos
Treatment for Patients Not Undergoing Transplant Made Simple
Myeloma Made Simple: Non-ASCT Transplant Eligible
Treatment for Patients Not Going to Transplant Made Simple! Join Dr. Joseph Mikhael in the latest episode of "Myeloma Made Simple" as he discusses effective therapies…
Videos
Bispecific Antibodies: Late Side Effects
Side effects to look out for in the later stages of bispecific treatment
Tune in to this video to see IMF Chief Medical Officer Dr. Joseph Mikhael break down the late side effects of bispecific antibodies, including infections, low white…
Videos
TALVEY (Talquetamab) a New First-in-Class Monoclonal Antibody Treatment for Myeloma Approved by the FDA on August 9th, 2023
TALVEY targets a unique receptor called GPRC5D on the surface of myeloma cells. It also targets CD3 on T lymphocytes, facilitating interaction between immune cells and…
News Article
On September 26, 2023, the City of Glendale in Los Angeles County awarded a proclamation to the International Myeloma Foundation for Blood Cancer Awareness Month.
.video-responsive{
overflow:hidden;
padding-bottom:56.25%;
position:relative;
height:0;
}
.video-responsive iframe{…
Page
Phase I Clinical Trial The main goal of a phase I clinical trial is to determine the maximum tolerated dose (MTD) and safety profile of a new drug or a new combination of drugs. A phase I study may be the first testing of a new treatment in humans. However, when it comes to combination…
Page
Historically, clinical trials have lacked diverse representation in general and in myeloma clinical trials in particular. In the U.S., approximately 20% of all myeloma patients are of African descent, but only 5%–8% of patients in myeloma clinical trials are of African descent.
Why…
Videos
M-Power Tampa Community Event On Health Empowerment.
Focusing on awareness of multiple myeloma in the African American community and living a healthier life.
The M-Power Project realizes the IMF Diversity Initiative's vision, enhancing outcomes for African-American myeloma patients. Though…
Page
Philanthropic contributions of any size and frequency support’s IMF’s ability to take the long road and invest in innovative research that can make a significant life-changing difference in the lives of myeloma patients, their caregivers, and other loved ones. Your gift can be a one-time monthly or…
Videos
Bispecific Antibodies: Early Side Effects
Side effects to look out for within the first month of bispecific treatment
Dr. Joseph Mikhael, IMF Chief Medical Officer, guides viewers through the side effects they can expect within the first month of bispecific myeloma treatment.…
Videos
Despite a Noticeable Decrease in COVID-19 Cases, Recent Weeks Have Witnessed a Slight Rise in Infections
The emergence of a new COVID-19 variant known as “Eris” has caught attention. Alongside Eris, there are three other variants circulating, contributing to the need for continued…
News Article
IMF President and CEO Yelak Biru attended a policy summit in Washington, D.C., where he along with a National Comprehensive Cancer Network (NCCN) working group presented new recommendations for measuring and addressing health-related social needs (HRSN) for people with cancer. Learn more at…
Videos
Using Different Targets to Destroy Multiple Myeloma
How Bispecifics Attach to Myeloma Cells
Join Dr. Joseph Mikhael, IMF Chief Medical Officer, to learn how different bispecific antibodies work to destroy myeloma by attaching to antigens on myeloma cells.
Videos
Virtual Multiple Myeloma Community Workshop
A virtual multiple myeloma workshop addressing the needs specific to communities in the West region.
The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy,…
News Article
According to a September 11, 2023 press release from BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, the U.S. FDA "has approved APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic…
Videos
Current Tests to Monitor Myeloma and New Tests on the Horizon
In this week's Ask Dr. Durie, myeloma expert Dr. Brian G.M. Durie discusses the current state of myeloma monitoring tests, including routine blood counts and imaging, but highlights two upcoming game-changers expected in early…
News Article
NEW ORLEANS, September 7, 2023 — The International Myeloma Foundation (IMF), in partnership with the National Medical Association (NMA), the W. Montague Cobb Institute, and the Student National Medical Association (SNMA), sent a delegation of eleven IMF Medical Student Scholars for…
IMF Person
Sanjay Singh is a global finance and strategy leader who leverages his broad financial expertise to shape and influence business strategy and drive transformation. He is currently a Consultant and Board Member. He has worked as a Chief Financial Officer and Senior VP for Business Planning and…
IMF Person
Diagnosed with multiple myeloma in 1989 at age 33, Brian D. Novis founded the IMF in 1990, along with wife Susie, and Brian’s then-physician, Dr. Brian G.M. Durie. Together, the three join forces and set out to educate patients about the little-known blood cancer and available treatment options…